VolitionRX (VNRX) Given a $5.00 Price Target at Oppenheimer

Share on StockTwits

Oppenheimer set a $5.00 price objective on VolitionRX (NYSEAMERICAN:VNRX) in a research report report published on Friday morning. The brokerage currently has a buy rating on the medical research company’s stock.

VNRX traded up $0.03 on Friday, reaching $2.73. The stock had a trading volume of 15,304 shares, compared to its average volume of 108,530. VolitionRX has a fifty-two week low of $1.44 and a fifty-two week high of $4.00.

VolitionRX (NYSEAMERICAN:VNRX) last issued its earnings results on Wednesday, November 7th. The medical research company reported ($0.14) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.14).

In other news, Director Guy Archibald Innes bought 50,000 shares of the stock in a transaction on Thursday, August 16th. The stock was acquired at an average price of $2.00 per share, with a total value of $100,000.00. The transaction was disclosed in a filing with the SEC, which can be accessed through this link.

A hedge fund recently bought a new stake in VolitionRX stock. Leisure Capital Management purchased a new stake in VolitionRX Ltd (NYSEAMERICAN:VNRX) during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund purchased 72,479 shares of the medical research company’s stock, valued at approximately $188,000. Leisure Capital Management owned about 0.21% of VolitionRX at the end of the most recent quarter.

About VolitionRX

VolitionRX Limited, a life sciences company, engages in the development of blood tests to help diagnose a range of cancers worldwide. The company develops 39 epigenetic Nu.Q blood assays based on its Nucleosomics biomarker discovery platform. VolitionRX Limited is based in Singapore.

Featured Article: Bond

Receive News & Ratings for VolitionRX Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VolitionRX and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Intra-Cellular Therapies  Downgraded by Zacks Investment Research
Intra-Cellular Therapies Downgraded by Zacks Investment Research
Astronics  Upgraded to Hold by ValuEngine
Astronics Upgraded to Hold by ValuEngine
Cabot  Upgraded by ValuEngine to “Sell”
Cabot Upgraded by ValuEngine to “Sell”
Global Blood Therapeutics  Downgraded by ValuEngine to Buy
Global Blood Therapeutics Downgraded by ValuEngine to Buy
Head-To-Head Comparison: Anthem  and Advanzeon Solutions
Head-To-Head Comparison: Anthem and Advanzeon Solutions
ADDvantage Technologies Group  & W W Grainger  Head-To-Head Contrast
ADDvantage Technologies Group & W W Grainger Head-To-Head Contrast


Leave a Reply

© 2006-2018 Ticker Report